Table 2 Comparison of treatment outcomes between baseline and month 12.
Aflibercept group (n = 28) | Brolucizumab group (n = 17) | |||||
|---|---|---|---|---|---|---|
Baseline | 12 months | p value | Baseline | 12 months | p value | |
Best-corrected visual acuity (logMAR) | 0.24 ± 0.21 | 0.14 ± 0.12 | 0.020 | 0.29 ± 0.25 | 0.16 ± 0.14 | 0.030 |
Central macular thickness (µm) | 334.2 ± 78.3 | 231.4 ± 48.6 | 0.010 | 342.9 ± 84.8 | 227.8 ± 46.2 | 0.012 |
Subfoveal choroidal thickness (µm) | 293.4 ± 91.5 | 231.7 ± 57.9 | 0.001 | 298.6 ± 79.4 | 221.7 ± 64.8 | 0.001 |
Choriocapillaris/Sattler layer (µm) | 81.4 ± 23.2 | 70.5 ± 16.1 | 0.077 | 82.8 ± 30.9 | 67.2 ± 14.8 | 0.130 |
Haller layer (µm) | 211.2 ± 46.9 | 167.8 ± 21.5 | 0.024 | 215.0 ± 47.5 | 152.4 ± 26.1 | 0.030 |
Choroidal vascularity index (%) | 68.3 ± 3.4 | 69.8 ± 3.2 | 0.574 | 69.2 ± 3.2 | 75.4 ± 3.5 | 0.026 |
Choroidal neovascularization lesion area (mm2) | 3.7 ± 2.1 | 2.9 ± 2.0 | 0.041 | 3.6 ± 1.9 | 2.4 ± 1.6 | 0.024 |
Choriocapillaris flow density (%) | 45.2 ± 8.4 | 43.7 ± 6.7 | 0.225 | 46.4 ± 9.1 | 44.9 ± 8.2 | 0.154 |
